Wiley acquires drug discovery software developer SimBioSys
11 June 2014
Specialist information provider and publisher John Wiley has
announced that it has acquired SimBioSys Inc., a provider of
scientific software tools that facilitate the drug discovery
process. Terms were not disclosed.
SimBioSys is a pioneer in the field of computer-aided
retrosynthetic analysis where it supports chemists in the challenges
of organic synthesis. It was founded in 1996, privately held, and is
based in Toronto, Canada.
“Wiley has deep roots in top quality chemistry publishing with
high-profile international chemistry society partnerships and
extensive chemical databases, journals, books and references,” said
Steve Miron, Senior Vice President of Wiley’s Global Research
business. “By combining our traditional published content and
databases with machine learning algorithms, we can support chemists
in innovative research as they advance world knowledge.”
“The acquisition of SimBioSys accelerates the development of
Wiley Science Solutions, our integrated suite of workflow tools for
researchers,” said Dr. Mike Davis, Vice President and Managing
Director, Research Innovations “SymBioSys has developed technology
that enables the computer to learn organic chemistry. These tools
enable chemists working in industry and academia to find new and
better ways of synthesizing target compounds, saving them time and
The SimBioSys ARChem Route Designer is an expert system that
helps chemists design viable synthetic routes for target molecules.
ARChem’s knowledge of organic chemistry is automatically derived
from reaction databases such as Wiley’s CIRX Reaction Database.
Source: John Wiley & Sons Inc